ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AMS vs BGLC // EV/EBITDA & P/E VALUATION

American Shared Hospital Services (NYSE) VS. BioNexus Gene Lab Corp (NASDAQ) • 15-METRIC TALLY: AMS 8 — BGLC 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMS VS. BGLC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AMS BGLC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 18.00% 14.60% +3.40 AMS /gross-margins <GO>
Return on Invested Capital (ROIC) -13.80% -35.00% +21.20 AMS /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -12.80% -39.90% +27.10 AMS /operating-margins <GO>
Net Profit Margin -5.50% -40.20% +34.70 AMS /net-margins <GO>
Revenue Growth (YoY) -0.90% -21.90% +21.00 AMS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.46 2.12 -1.66 BGLC /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 AMS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.0 24.5 +17.54 AMS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $8.4M $2.9M $5.5M AMS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AMS REV BGLC REV AMS GROSS % BGLC GROSS % AMS FCF BGLC FCF
FY 2025 $28.1M $7.4M 18.0% 14.6% -$4.5M -$1.9M
FY 2024 $28.3M $9.5M 32.4% 13.6% -$7.8M -$2.3M
FY 2023 $21.3M $9.8M — — $5.7M -$1.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMS // BETA —
BGLC // BETA —